AIM
Aim Immunotech Inc
AMEX · Biotechnology
$1.14
-0.09 (-7.32%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.49M | 1.31M | 1.61M |
| Net Income | -287,322 | -292,011 | -275,194 |
| EPS | — | — | — |
| Profit Margin | -19.3% | -22.2% | -17.1% |
| Rev Growth | +0.1% | +20.5% | -9.2% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 1.16M | 1.16M | 1.06M |
| Total Equity | 1.40M | 1.39M | 1.56M |
| D/E Ratio | 0.83 | 0.83 | 0.68 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -396,733 | -341,169 | -390,753 |
| Free Cash Flow | -189,259 | -173,511 | -203,411 |